PharmaEssentia revenue and financials
$1,205.00Change from previous close: +2.55%Absolute change: +$30.00
In the fiscal year ended December 2025, PharmaEssentia reported revenue of $15.63B (+60.61% year over year). Net income was $5.05B, a net margin of 32.3%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +60.61%
- 2025 vs 2024
- Net income growth
- +70.13%
- 2025 vs 2024
- Net margin
- 32.3%
- 2024: 30.5%
Financial data
Amounts in millions of TWD; per-share values in TWD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total assets | 44,111 | 40,090 | 37,411 | — | 32,804 | 33,024 |
| Current assets | 33,589 | 30,923 | 29,044 | — | 25,771 | 26,899 |
| Cash and equivalents | 24,471 | 24,175 | 22,693 | — | 20,783 | 22,034 |
| Short-term investments | 24.2 | 24.3 | 24.1 | — | 22.0 | 24.2 |
| Inventory | 1,274 | 1,219 | 1,298 | — | 1,160 | 1,384 |
| Net property, plant and equipment | 6,320 | 5,930 | 5,290 | — | 4,048 | 3,825 |
| Long-term investments | 46.5 | 48.4 | 50.6 | — | 54.5 | — |
| Current liabilities | 6,364 | 4,737 | 4,681 | — | 3,342 | 2,967 |
| Accounts payable | 163 | 144 | 157 | — | 146 | 189 |
| Long-term debt | 41.8 | 43.3 | 44.8 | — | 47.8 | 49.3 |
| Total debt | 1,022 | 961 | 856 | — | 945 | 985 |
| Total liabilities | 7,295 | 5,635 | 5,436 | — | 4,259 | 3,900 |
| Total equity (incl. minority) | 36,816 | 34,454 | 31,975 | — | 28,545 | 29,123 |
| Retained earnings | 9,753 | 9,097 | 6,947 | — | 3,998 | 4,237 |